Viral antibodies in multiple sclerosis

Ferrante P.*, Caputo D.**, Barbesfi S.*, Fasan M.*

*Istituto di Virologia, Università di Milano
**Centro Studi Sclerosi Multipla, Università di Milano,
Ospedale Generale Provinciale "S. Antonio Abate" Gallarate

The sera of 176 MS patients and of 150 healthy adult controls were assayed for antibodies against mumps, rubella, Sendai and herpes simplex viruses, a higher prevalence of measles c.f.a. having already been demonstrated in the MS patients. The CSF of 48 of the MS patients were subjected to the same tests. The patients differed from the controls in a higher prevalence of h.i.a. to mumps and of c.f.a. to herpes simplex. For the latter, but not for the former, the prevalence was statistically higher only in patients treated with immunosuppressants. To date measles seems to be the most seriously incriminated virus in the etiopathogenesis of MS, mumps ranking second.

Key-words: Multiple sclerosis -- viral antibodies

Introduction

Several, mainly epidemiological, observations suggest that one or more viruses are involved in the etiology of multiple sclerosis (MS) [13, 5, 18]. Unlike in subacute sclerosing panencephalitis (SSPE) or progressive rubella panencephalitis (PRP), in which typical antibody patterns and viral persistence in the central nervous system (CNS) are observed, in MS no one virus has emerged from virological studies as the etiological agent. With the exception of some controversial reports [4, 7, 15, 3] viruses have not been isolated from the CNS of MS patients and the antibody findings are not highly characteristic.

However, since Adams and Imagawa [1] observed increased measles titers in patients with MS, many studies have been made on the behavior of antibodies against measles and other viruses in the serum and cerebrospinal fluid (CSF) of such patients [17]. Paramyxoviruses have been more thoroughly investigated than others because of the similarities of the viral envelope to the plasma membrane of the host cells [2]. We report here the results of titrations of antibodies to mumps, rubella, Sendai and Herpes simplex viruses in the sera and CSF of MS patients and healthy controls. Data on the measles antibodies in the same groups of patients and controls have already been published [61].

Subjects and methods

Specimens. Sera were collected from 176 MS patients and CSF from 48 of them. In all cases the clinical diagnosis was confirmed at the Multiple Sclerosis Research Center, Gallarate (VA), according to the criteria of McDonald and Holliday [16]. Sera from 150 healthy controls in the 20-50 year age range were also tested.

Antibody assay. Sera and CSF specimens were assayed for hemagglutination inhibition (h.i.e.) to mumps, Sendal (murine parainfluenza type 1 and rubella viruses and for complement fixing antibody (c.f.a.) to herpes simplex and to the s antigen of mumps and Sendal viruses. As source of antigen in the rubella h.i. test and in the herpes simplex c.f. test commercial preparations were used; h.i. and soluble complement fixing antigens to mumps and Sendai viruses were pre-
pared in embryonated eggs according to the method indicated for mumps virus [8]. Antibody titrations were performed with the microtiter technique according to standard procedures [11]. 2 fold dilutions of sera starting from 1:4 were tested in c.f. test. Aspecific hemagglutination inhibitors to mumps and Sendai viruses were removed from the sera by treatment with RDE (Receptor Destroying Enzyme), those to rubella virus by treatment with heparin manganous chloride. Starting dilutions of sera were 1:5 in h.i. test for the former viruses and 1:8 for the latter. CSF specimens were checked undiluted and in 2 fold dilutions.

Results

Results of viral antibodies titration in the sera of MS patients and controls are presented in Table 1 as percentage of positives and geometric mean titres (GMT). MS patients have been divided into two groups: those treated with immunosuppressive drugs and those not so treated. In the computation of the GMT subjects who were negative for the specific viral antigen were assigned the titer of the next lowest dilution. No difference in GMT was found in three groups under study.

The prevalence of subjects with mumps h.i.e. was significantly higher among patients, both treated and untreated, than in controls (P < 0.001 - X² test). Moreover MS patients had a higher prevalence of CF serum antibodies against herpes simplex virus than controls (0.01 > P > 0.001) but the difference is statistically significant for the treated patients (0.01 > P > 0.001), not for the untreated ones (P > 0.05). CSF from 48 MS patients were also tested for viral antibodies and only one was found positive: CF antibodies to herpes simplex virus were detectable in the undiluted specimen.

Discussion

There has been little or no direct evidence of the involvement of one or more viral agents in the etiopathogenesis of MS. It is therefore not surprising that a lot of emphasis has been put on attempts to gain indirect evidence through seroepidemiological investigations.

As a part of a wide-ranging study on the relationship between viruses and MS, viral antibodies were preliminarily checked in the sera of 176 patients and in a suitable control group of healthy adults. After measles [6], other enveloped viruses, namely mumps, Sendai, rubella and herpes simplex were considered. For the two paramyxoviruses, besides antibodies against the surface antigen haemagglutinin, antibodies against the internal antigens were also titrated. That because the persistence of paramyxovirus-like nucleocapsids in CNS cells have already been proved in other chronic neurological disorders [14] and, by some authors, also in MS [15].

As in other similar investigations evaluation of results is rather difficult. Differences between MS patients and controls were found only in the prevalence of h.i.a, against mumps and of c.f.a. against herpes simplex, both in favour of the patients. But a further analysis of the data shows that, for herpes simplex, but not for mumps, only patients treated with immunosuppressive drugs had statistically higher antibody prevalence than controls. Incidentally also the only patient, out of 48, who had c.f.a. to herpes simplex in CSF belonged to the treated group. This finding suggests caution in evaluating antibody results to viruses undergoing reactivation, like

**Table I. Viral antibodies in sera from MS patients and controls**

| Test (1) | MS Patients Treated (N=146) | MS Patients Untreated (N=30) | Controls (N=150) | χ² (2) |
|---------|---------------------------|-----------------------------|------------------|--------|
|         | % Positive | Geometric(3) mean titers | % Positive | Geometric(3) mean titers | % Positive | Geometric(3) mean titers |        |
| Mumps   |           |                         |           |                         |           |                         |        |
| HI      | 61.0      | 1:7.5                    | 63.3      | 1:8.6                    | 30.7      | 1:7.6                    | P<0.001(4) |
| CF      | 72.6      | 1:5.5                    | 60        | 1:4.8                    | 75.8      | 1:5                      | P>0.05   |
| Parainfluenza type 1 | 26.0      | 1:7.2                    | 16.7      | 1:6.6                    | 34.6      | 1:7                      | P>0.05   |
| (Sendai) | CF         | 63.0                     | 1:5.6     | 43.3                     | 52.9      | 1:5                      | P>0.05   |
| Rubella | 90.4      | 1:43.6                   | 86.7      | 1:39.1                   | 92.1      | 1:44                     | P>0.05   |
| Herpes Simplex type 1 | CF         | 93.1                     | 1:26.1    | 93.3                     | 1:27.3    | 82.8                     | 1:22.9   |

(1) HI = Haemagglutination Inhibition; CF = complement fixation.
(2) X² Test, with Yates correction, comparing frequencies of patients under treatment, untreated and controls (2 d.f.).
(3) for each test GMT of the three groups were compared with t student test.
(4) treated patients versus controls P<0.001; untreated patients versus controls P<0.01 (1 d.f.).
(5) treated patients versus controls 0.01>P>0.001; untreated patients versus controls P>0.05 (1 d.f.).
Ferrante: Viral antibodies in MS

herpes viruses, when chronic patients under prolonged therapy are concerned.

Combining all the observations on viral antibody patterns in a large series of MS patients, we found a different behaviour between patients and controls only for two paramyxoviruses: measles in the first place, [6] and then mumps.

Although we are aware that viral antibody response in MS patients may be influenced by several factors like HLA antigens [10], stage and course [9, 12] of the disease, type of treatment etc., it is difficult to avoid the impression that these two viruses which emerge as the most suspicious in almost all the seroepidemiological investigations, may be somehow involved in the etiopathogenesis of MS.

Sommario

Sono riportati i risultati delle titolazioni anticorporali verso i virus della parotite, della rosolia, Sendai ed herpes simplex nel siero di 176 pazienti affetti da Sclerosi Multipla e di 150 soggetti sani di controllo, nonché nel liquor di 48 dei malati. In precedenza negli stessi gruppi di soggetti erano stati studiati gli anticorpi antimorbilli.

Differenze tra i malati e i controlli sono state riscontrate solo per la prevalenza nel siero degli anticorpi inibenti l’emagglutinazione antiparotite e degli anticorpi fissanti il complemento verso l’herpes simplex. Va sottolineato che, al contrario di quanto si è verificato per il virus della parotite, solo i pazienti sottoposti a terapia con farmaci immunodepressivi presentavano una prevalenza degli anticorpi fissanti il complemento verso l’herpes simplex statisticamente maggiore dei controlli. Sulla base delle presenti e di precedenti osservazioni, sembra che il morbillo in primo luogo e la parotite siano i virus per i quali esistono maggiori evidenze di un coinvolgimento nell’etio-patogenesi della Sclerosi Multipla.

Address reprint requests to: Dr. P. Ferrante
Istituto di Virologia dell’Università
Via Pascal 38 --20133 Milano (Italia)

References

[1] ADAMS M., IMAGAWA D.T.: Measles antibodies in multiple sclerosis; Proc. Soc. Exp. Biol. Med., 111, 562-566, 1962.
[2] BERGAMINIF.: Slow virus e malattie croniche del sistema nervoso centrale. Boll. Ist. Sieroter. Milanese, 56, 589-596, 1977.
[3] BURKS J.S., DEVALD B.L., JANKOVSKY L.D., GERDES J.C.: Two Coronavirus Isolated from Central Nervous System Tissue of two Multiple Sclerosis Patients. Science, 209, 933-934, 1980.
[4] CARP P.L., LICURSI P.C., MERZ P.A., MERZ G.S.: Decreased percentage of polymorphonuclear neutrophils in mouse peripheral blood after inoculation with material from multiple sclerosis patients. J. of Exp. Med., 136, 618-628, 1972.
[5] COOK S.D., DOWLING P.C.: Multiple sclerosis and viruses: An overview; Neurology, 30, 80-91, 1980
[6] FERRANTE P., CAPUTOD., FASANM., BARBESTI S.: Anticorpi sierici e liquorali verso il virus del morbilli in pazienti affetti da sclerosi multipla. In press "Archivio per le scienze mediche", 1981.
[7] FIELDE.J.: Transmission experiments with multiple sclerosis: an interim report. Brit. Med. J., 2, 564-565, 1966.
[8] HENLEW.: Mumps Virus: In: LENNETTEE.H., SCHMIDTN.J.: "Diagnostic procedures for Viral and Rickettsial Infections". 4th Ed. Am. Pub. Hlth. Ass., Washington, 457-482, 1969.
[9] HOHER P.G., KUWERT E.K., POSER S. and BAUERH.J.: Kinetics of Measles Virus Antibodies in Multiple Sclerosis Patients in Correlation to the Clinical Course of the Disease. Progress in Multiple Sclerosis Research. Ed. Bauer H.J., Poser S. Ritter G. Springer-Verlag Berlin Heidelberg New York, 271-277, 1980.
[10] LEHRICH H., ARNASON B. G. W.: Histocompatibility Types and Viral Antibodies. Arch. Neurol., 33, 404-405, 1976.
[11] LENNETTE H.: General principles underlying laboratory diagnosis of viral and rickettsial infections. In LENNETTE H., SCHMIDTIN J., "Diagnostic procedures for Viral and Rickettsial Infections". 4th Ed. Am. Pub. Hlth. Ass., Washington, 1-65, 1969.
[12] MATVEEVA T., PILLE E. R., Dr. AKANOVAL N., ANDREEVAA P.: Investigation on the role of viral antibodies in the pathogenesis of Multiple Sclerosis. Acta Virol., 24, 989-995, 1980.
[13] MEULEN V. ter, KATZ M., MOLLER D.: Subacute Sclerosing Panencephalitis. C.T. in Microbiology, 57, 138-139, 1972.
[14] MEULEN, ter, KATZM., MOLLERD.: Subacute Sclerosing Panencephalitis. C.T. in Microbiology, 57, 1-38, 1972.
[15] MEULEN, ter, KOPROWSKIH., IWASAKY., et al.: Fusion of cultured multiple-sclerosis brain cells with indicator cells. Presence of nucleocap-
sids and virions and isolation of parainfluenza type virus. Lancet, II, 1-5, 1972.

Mc DONALD W.I., HALLIDAY A.M.: Diagnosis and classification of multiple sclerosis. Br. Med. Bull., 33, 4-8.

[17] NORRBY E.: Viral Antibodies in Multiple Sclerosis. Prog. Med. Virol., 24, 1-39, 1978.

[18] WAKSMAN B.H.: Current trends in multiple sclerosis research. Immunology today, 2, 87-93, 1981.